Union for Advasure (med det tidligere navn Bayovac CSF E2) den 2. februar 2001.
The European Commission granted a marketing authorisation valid throughout the European Union for Advasure (previously called Bayovac CSF E2) on 2 February 2001 and the current marketing cin